Shruti Patel, MD

Breast Cancer

A new study that suggests ovarian suppression reduces the risk of breast cancer recurrence risk can be used to personalize care, one expert writes. 

Analysis Shows Value of Ovarian Suppression

Ovarian Suppression

Meta-Analysis Shows Value of Ovarian Suppression in Patients With Early Breast Cancer

Inas Abuali, MD, FACP

Stefania Morganti, MD

Our expert panel reviews three recent papers, each looking for ways to optimize treatment for a subgroup of breast cancer patients. Shruti Patel, MD, reviews data from the HOPE trial looking at the cost of low-intensity adjuvant chemotherapy in older women. Inas Abuali, MD, looks at a study on treatments for de novo metastatic HER2-low disease. Stefania Morganti, MD, discusses a study that suggests neoadjuvant carboplatin should be considered for more women with triple-negative disease.

Our experts review studies on the problem of low-intensity chemo, de novo metastatic HER2-low disease, and chemotherapy for triple negative tumors.

Improving Breast Cancer Outcomes by Subgroups

Improving Outcomes

Improving Breast Cancer Outcomes One Subgroup at a Time

Albert Grinshpun, MD, MSc

Medical Oncologist; Instructor in Medicine

Philip D. Poorvu, MD

Dong Won Kim, MD

Our experts review three abstracts in ESR1-mutant HR-positive, HER2-negative metastatic breast cancer from the PADA-1, ELAINE-1, and EMERALD trials in the November 2022 Breast Cancer Journal Scan.

Female doctor looking at test results of her patient.

Tackling ESR1-driven Resistance in MBC

ESR1 Resistance

Is the Way to Tackle ESR1-driven Resistance in Metastatic Breast Cancer to Monitor ctDNA?

Shruti Patel, MD, is an oncology fellow at Stanford University in Palo Alto, California.

Related

Analysis Shows Value of Ovarian Suppression

Analysis Shows Value of Ovarian Suppression

Improving Breast Cancer Outcomes by Subgroups

Improving Breast Cancer Outcomes by Subgroups

Tackling ESR1-driven Resistance in MBC

Tackling ESR1-driven Resistance in MBC